KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Taxes (2016 - 2025)

Astrazeneca (AZN) has 3 years of Current Taxes data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Current Taxes fell 22.9% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 22.9%, while the annual FY2025 figure was $1.1 billion, 22.9% down from the prior year.
  • Current Taxes reached $1.1 billion in Q4 2025 per AZN's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Current Taxes topped out at $1.6 billion in Q4 2023 and bottomed at $1.1 billion in Q4 2025.
  • Average Current Taxes over 3 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
  • Peak YoY movement for Current Taxes: decreased 11.24% in 2024, then decreased 22.9% in 2025.
  • A 3-year view of Current Taxes shows it stood at $1.6 billion in 2023, then decreased by 11.24% to $1.4 billion in 2024, then fell by 22.9% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $1.1 billion in Q4 2025, $1.4 billion in Q4 2024, and $1.6 billion in Q4 2023.